Combination of EGFR inhibitor and mek inhibitor for use in the treatment of nras mutated cancer
MA39841AUndetermined Publication Date: 2017-02-08ASTRAZENECA AB +1
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MA39841
- Authority / Receiving Office
- MA · MA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2014-06-18
- Filing Date
- 2015-04-02
- Publication Date
- 2017-02-08
Abstract
The invention relates to the methods for identifying resistance to cancer therapy, by identification of an e63k nras mutation, a g12v nras mutation or a gain of copy number of
Need to check novelty before this filing date? Find Prior Art